Cefazolin/clindamycin

PreclinicalSmall molecule

TTianjin Medical University Cancer Institute and Hospital

Cefazolin/clindamycin is one of 4 small molecule programs targeting Breast Reconstruction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast ReconstructionUnknown status

Breast ReconstructionPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Breast Reconstruction

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Phase 1

1 2

Bupivicaine

TThomas Jefferson University

Preclinical

1 3

Fibrin Sealant

GGynecologic Oncology Group

Preclinical

1 4

Cefazolin/clindamycin

TTianjin Medical University Cancer Institute and Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Reconstruction1 trial

Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03742908·291 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cefazolin/clindamycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cefazolin/clindamycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cefazolin/clindamycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTianjin Medical University Cancer Institute and Hospital

Cefazolin/clindamycin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Reconstruction1 trial

References

Drug Info

Quick Facts

Related News